
|Videos|February 17, 2022
Darolutamide well tolerated in patients with nmCRPC who have comorbidities
Author(s)Urology Times staff
“[These favorable findings just speak] to the complexity of the health index for these patients,” says Neal D. Shore, MD, FACS.
Advertisement
In this video, Neal D. Shore, MD, FACS, discusses the background and findings of the study, “Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












